NasdaqGS - Nasdaq Real Time Price USD

AnaptysBio, Inc. (ANAB)

23.19

-0.51

(-2.15%)

At close: June 9 at 4:00:00 PM EDT

23.89

+0.70

+(3.02%)

Pre-Market: 7:03:32 AM EDT

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month blinded treatment periodFavorable safety and tolerability, particularly when compared to standard of care biologics or JAKsMax response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50Durable responses for at least two months off drug, with

GlobeNewswire 6 days ago

ANAB
-2.15%
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anapty

GlobeNewswire 13 days ago

ANAB
-2.15%
AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

We recently published a list of 11 Unstoppable Growth Stocks to Invest in Now. In this article, we are going to take a look at where AnaptysBio, Inc. (NASDAQ:ANAB) stands against other unstoppable growth stocks to invest in now. BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions. […]

Insider Monkey 28 days ago

ANAB
-2.15%

^RUT

BLK
Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results

There's been a notable change in appetite for AnaptysBio, Inc. ( NASDAQ:ANAB ) shares in the week since its quarterly...

Simply Wall St. last month

ANAB
-2.15%
AnaptysBio First Quarter 2025 Earnings: Beats Expectations

AnaptysBio ( NASDAQ:ANAB ) First Quarter 2025 Results Key Financial Results Revenue: US$27.8m (up 287% from 1Q 2024...

Simply Wall St. last month

ANAB
-2.15%
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of 1.54% and 52.31%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ANAB
-2.15%
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of JuneInitial Phase 2 data for rosnilimab in ulcerative colitis (UC) on track for Q4 2025Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulatorAuthorized a $75 million Stock Repurchase Program in March 2025 and reiterating cash runway t

GlobeNewswire last month

ANAB
-2.15%
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. “It is a pleasure to welcome John to our Board,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. “John brings decades of experience and an extens

GlobeNewswire last month

XERS

DSGN

ANAB
-2.15%
AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

AnaptysBio (ANAB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks 2 months ago

ANAB
-2.15%

MGTX
Anaptys Announces Stock Repurchase Plan

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding common stock, par value $0.001 per share. Anaptys has cash, cash equivalents and investments greater than $420 million as of December 31, 2024, and anticip

GlobeNewswire 2 months ago

ANAB
-2.15%
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market rebounded from a turbulent week, fueled by easing fears of a government shutdown and renewed confidence in the U.S. economy. Fresh February data signaled that inflation was cooling in line with the Federal Reserve’s targets, helping to calm concerns about economic strain. Looking at the bigger picture, Wells Fargo’s senior global market strategist Scott Wren sees plenty of

TipRanks 2 months ago

ANAB
-2.15%

ANNX
AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of 55.28% and 324.09%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

ANAB
-2.15%
Anaptys Announces Participation in March Investor Conferences

SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen 45th Annual Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetingsDate

GlobeNewswire 3 months ago

ANAB
-2.15%
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and translational data for rosnilimab in RA in Q2 2025Top-line Phase 2 data for rosnilimab in ulcerative colitis (UC), moved up to Q4 2025Phase 1a trial in healthy volunteers ongoing for ANB033, our CD122 antagonist, and Phase 1a trial to initiate this quarter for ANB101, our BDCA2 modulatorAnnounced excl

GlobeNewswire 3 months ago

ANAB
-2.15%
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS-28 CRP and key secondary endpoints were met. However, efficacy was numerically undifferentiated from peresolimab and the firm says rosnilimab “looks like a me-too in RA.” Confusion and questions around handing of the placebo group post double-blinded study period through week 12 raises questions about the

TipRanks 3 months ago

ANAB
-2.15%
Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks 3 months ago

ANAB
-2.15%

ATRC
AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio (ANAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks 3 months ago

ANAB
-2.15%
AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio’s trial saw 69% of patients treated with rosnilimab achieve low disease activity by week 12.

Clinical Trials Arena 3 months ago

ANAB
-2.15%

GLDAF
AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

AnaptysBio stock whipsawed Wednesday despite promising results for its experimental rheumatoid arthritis treatment.

Investor's Business Daily 3 months ago

ANAB
-2.15%
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placeboAchieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDADemonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially

GlobeNewswire 3 months ago

ANAB
-2.15%

Performance Overview

Return	ANAB	S&P 500 (^GSPC)
YTD	+75.15%	+2.11%
1-Year	-1.02%	+12.32%
3-Year	+2.07%	+49.48%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AnaptysBio, Inc. (ANAB)

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now

Analysts Are Upgrading AnaptysBio, Inc. (NASDAQ:ANAB) After Its Latest Results

AnaptysBio First Quarter 2025 Earnings: Beats Expectations

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last?

Anaptys Announces Stock Repurchase Plan

Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

Anaptys Announces Participation in March Investor Conferences

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data

Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year?

AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains?

AnaptysBio achieves ‘highest ever’ results in Phase II rheumatoid arthritis trial

AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Performance Overview